



Drug Use Research & Management Program  
OHA Division of Medical Assistance Programs  
500 Summer Street NE, E35; Salem, OR 97301-1079  
Phone 503-947-5220 | Fax 503-947-1119



### Oregon Pharmacy & Therapeutics Committee

Thursday, November 17, 2011 2:00-5:00 PM  
Barbara Roberts Human Resources Building Rm#137  
500 Summer Street NE, Salem, OR  
DRAFT Meeting Minutes

**Members Present:** Andris Antoniskis, MD; Joshua Bishop, PharmD; Zahia Esber, MD; Tracy Klein, PhD, FNP; Phillip Levine, PhD; Meena Mital, MD; William Origer, MD; David Pass, MD; Stacy Ramirez, PharmD; James Slater, PharmD; Cathy Zehrung, RPh

**Staff Present:** Dean Haxby, PharmD; Roger Citron, RPh; Megan Herink, PharmD, BCPS; Ann Hamer, PharmD, BCPP; Kathy Sentena, PharmD; Ted Williams, PharmD, BCPS; Valerie Smith; Trevor Douglass, DC, MPH; Richard Holsapple, RPh; Ralph Magrish, MPA

**Audience Present:** Shannon Beatty (Med Immune); Linda Krueger (Eli Lilly); Venus Holder (Eli Lilly); Deron Grothe (Teva); Jim Graves (BMS); Bob Viadorx (BMS); John Stockton (Astellas); Amy Burus (OSU/OHSU Cop); David Barba (Forest); Barry Benson (Merck); Anne Marie Licos (Med Immune); Jeana Colabianchi (Sunovion); Lori Howarth (Bayer); Kate Ryan (Astra Zeneca); Dave Barrows (Merck); Tom Barrows (Merck); Cheryl Fletcher (Abbott); Bruce Smith (GSK); Jim Hoover (Bayer); Kathy Kirk (OPMC); Kathy Hahn (OPMC); Don Stoches (Novartis); Trish McDaid-O'Neill (Astra Zeneca); Darlene Halverson (Astra Zeneca); James Mattencchi (MSD); Paul Nielsen (Med Immune); Shane Hall (Purdue); Mike Willett (Pfizer)

#### I. CALL TO ORDER

- a. The meeting was called to order at 2:10 pm and introductions were made
- b. Presentation by Dr. Bruce Goldberg, Director OHA
- c. Presentation by Linda Grimms, Legal Counsel to OHA
- d. Conflict of interest declaration; no new conflicts were disclosed

#### II. ELECTION of CHAIR and VICE CHAIR

- a. Dr. William Origer was nominated to chair by the committee

**ACTION:** Committee voted unanimously to appoint Dr. Origer as chair

- b. Dr. Tracy Klein was nominated as vice-chair of the committee

**ACTION:** Committee voted unanimously to appoint Dr. Klein as vice chair

SUSPEND P&T MEETING

#### III. RULES ADVISORY COMMITTEE for TEMP RULES

- a. Minutes from this meeting were recorded separately

CONTINUE P&T MEETING

#### IV. PROCESS

- a. Members were asked to review a draft document and provide feedback at the next meeting

**ACTION:** No action at this time

## V. PLANNING

- b. Future meeting dates, times and locations were discussed

**ACTION:** Future meetings will be held on the last Thursday of each month beginning in January 2012 from approximately 1-4 pm in the SW Portland Metro area

## VI. NEW BUSINESS

- a. Dr. Sentena presented a new drug evaluation on Prasugrel. Public comment was offered by Linda Krueger from Eli Lilly.
- b. Dr. Sentena presented new drug evaluation on Ticagrelor. Public comment was offered by Kate Ryan from Astra Zeneca.

**ACTION:** Committee approved prior authorization criteria after adding the following:

- Diagnosis codes for the approved drug indications
- Length of treatment allowed for up to 12 months
- Allow for continuation of therapy for 30 days after hospitalization
- Grandfather patients currently taking medications for 12 months
- Make Prasugrel 2<sup>nd</sup> line and Ticagrelor 3<sup>rd</sup> line therapy

## VII. REPORTS/ DUR ACTIVITIES

- a. The committee did not review the Methadone / LAO Drug Use Evaluation (DUE); however public comment was offered by Kathy Kirk and Kathy Hahn from Oregon Pain Management Commission

The meeting adjourned at approximately 5:25 pm